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Background: Numerous natural products are marketed and sold claiming to decrease body weight and fat, but
few undergo finished product-specific research demonstrating their safety and efficacy.
Objective: To determine the safety and efficacy of a multi-ingredient supplement containing primarily raspberry
ketone, caffeine, capsaicin, garlic, ginger and Citrus aurantium (Prograde Metabolism™ [METABO]) as an adjunct to
an eight-week weight loss program.
Methods: Using a randomized, placebo-controlled, double-blind design, 70 obese but otherwise healthy subjects
were randomly assigned to METABO or a placebo and underwent 8 weeks of daily supplementation, a calorie
restricted diet, and exercise training. Subjects were tested for changes in body composition, serum adipocytokines
(adiponectin, resistin, leptin, TNF-α, IL-6) and markers of health including heart rate and blood pressure.
Results: Of the 45 subjects who completed the study, significant differences were observed in: body weight
(METABO -2.0% vs. placebo -0.5%, P < 0.01), fat mass (METABO -7.8 vs. placebo -2.8%, P < 0.001), lean mass
(METABO +3.4% vs. placebo +0.8%, P < 0.03), waist girth (METABO -2.0% vs. placebo -0.2%, P < 0.0007), hip girth
(METABO -1.7% vs. placebo -0.4%, P < 0.003), and energy levels per anchored visual analogue scale (VAS) (METABO +
29.3% vs. placebo +5.1%, P < 0.04). During the first 4 weeks, effects/trends for maintaining elevated serum leptin
(P < 0.03) and decreased serum resistin (P < 0.08) in the METABO group vs. placebo were also observed. No changes
in systemic hemodynamics, clinical blood chemistries, adverse events, or dietary intake were noted between groups.
Conclusions: METABO administration is a safe and effective adjunct to an eight-week diet and exercise weight loss
program by augmenting improvements in body composition, waist and hip girth. Adherence to the eight-week weight
loss program also led to beneficial changes in body fat in placebo. Ongoing studies to confirm these results and clarify
the mechanisms (i.e., biochemical and neuroendocrine mediators) by which METABO exerts the observed salutary
effects are being conducted.
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Obesity, particularly central adiposity, has been increas-
ingly cited as a major health issue in recent decades. In-
deed, some of the leading causes of preventable death
and disability, including heart disease, stroke, type 2
diabetes, degenerative joint disease, low back pain, and
specific types of cancer are obesity-related [1]. In the
United States, more than one-third of adults (35.7%) are
obese [2]. Annual obesity-related medical costs in the
United States were estimated to be as high as $147
billion in 2009 [3].
Excess body weight is also a major risk factor for the
development of Metabolic Syndrome. Metabolic Syn-
drome is a constellation of medical disorders including
hypertension, central adiposity, hyperglycemia and dys-
lipidemia [4,5] that increase the risk of premature car-
diovascular disease. Adipocytokines (including leptin,
tumor necrosis factor-α, interleukin-6, resistin, visfatin, ret-
inol binding protein-4, angiotensinogen and adiponectin)
are signaling cytokines produced by adipose tissue. Adipose
tissue acts as an endocrine organ producing adipocytokines
to regulate insulin signaling, vascular tone, carbohydrate
and lipid metabolism, and the inflammatory response.
Dysregulation of certain adipocytokines can contribute to
insulin resistance, amplified systemic inflammation and
lead to the development of Metabolic Syndrome and
hypertension [6]. For example, plasma levels of adipo-
nectin have been reported to be significantly reduced in
obese humans [7] and in patients with type-2 diabetes
mellitus, hypertension and metabolic syndrome [8-11].
Alternative methods to aid weight loss include meal
replacement preparations, and nutritional supplements
such as vitamins, mineral, and botanicals. Raspberry
ketone is an ingredient found in raspberries (Rubus
idaeus) that may have weight loss potential given prelim-
inary findings in rodents and cell cultures, i.e. prevention
of weight gain during a high-fat diet, and enhanced
norepinephrine-lipolysis, increased adiponectin expres-
sion, and translocation of hormone-sensitive lipase in adi-
pocytes [12,13]. To date, however, the effects of raspberry
ketone in humans remain unexplored. Many weight loss
supplements include caffeine and capsaicin since they are
known to increase energy expenditure by up to 13% and
have been proposed to counteract the decrease in meta-
bolic rate that often accompanies weight loss [14]. In
humans, oral ingestion of certain capsaicinoids, (active
component of chilli peppers from the genus Capsicum)
has been shown to increase energy expenditure, lipolysis
and fat oxidation [15], activate brown adipose tissue [16]
and stimulate the systemic release of norepinephrine
[15,17]. Bioactive compounds found in the rhizomes of
ginger (Zingiber officinale) and garlic (Allium sativum)
extracts have been shown to influence many key features
of the metabolic syndrome by modulating adipocytokinesecretion from adipose tissue, reducing body fat accu-
mulation, decreasing circulating insulin and markers of
systemic inflammation in murine and cell culture
models, with similar findings emerging from studies in
humans [18-21]. Extracts of Citrus aurantium, standardized
for p-synephrine and other bioactive amines have been
shown to increase resting metabolic rate and enhance
weight loss in human clinical trials [22].
Prograde Metabolism™ (METABO) is a multi-ingre-
dient dietary supplement that contains primarily rasp-
berry ketone, caffeine, capsaicin, garlic, ginger and
Citrus aurantium and is suggested to be used in com-
bination with an exercise and nutrition program. The
purpose of this study was to determine the safety and
efficacy of METABO as an adjunct to an 8-week weight
loss program. Primary endpoints included determin-
ation of the effect of this product on body composition
and various anthropometric measures. Secondary end-
points included determination of safety information via
measurement of systemic hemodynamics and standard
clinical chemistry panels of sera and plasma.
Methods
Subjects
A total of 70 recreationally active males and females
between the ages of 21 and 45 years were recruited to
participate in the study. In this study, recreationally
active was defined as participating in less than or equal
to two exercise sessions (aerobic or anaerobic activity)
per week over the previous 30 days. Subjects were
required to have a body mass index (BMI) greater than
27 kg/m2 and body fat greater than 20% (for males) or
greater than 25% (for females). Subjects were excluded if
they had used weight-loss supplements within the 30 days
prior to the start of the study, had gained or lost more
than 4.5 kg over the previous 30 days, were currently
taking medications that alter insulin sensitivity, or were
using lipid lowering or antihypertensive drugs. Subjects
were also excluded if they had metabolic disorders,
heart disease, hypertension, a known allergy to any in-
gredients in the supplement or placebo or had smoked
cigarettes in the last six months. Prior to being enrolled
in the study, all subjects underwent a physical examin-
ation by a licensed physician, 12-lead electrocardio-
gram, health history screen and provided written
informed consent. All procedures were approved by an
independent Institutional Review Board (IntegReview,
Austin, TX; protocol # PRO-002, approved 09/16/2011)
and were conducted in accordance with the revised
Declaration of Helsinki (2008).
Experimental design
This study utilized a randomized, placebo-controlled,
parallel-group, double-blind design. Subjects were mat-
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ized into placebo or METABO groups. The placebo
consisted of rice flour while the main ingredients of the
METABO formula included raspberry ketone, caffeine,
capsaicin, garlic organosulfur compounds, gingerols,
shogaols, Citrus aurantium and related alkaloids, B vita-
mins, and chromium (see Figure 1 for the Supplement
Facts panel). Capsules were produced in accordance with
current Good Manufacturing Practices (cGMP) in a
United States Food and Drug Administration (FDA) reg-
istered facility. Prior to production, all raw materials
were tested for purity and potency. A sample of the lot
and batch from the placebo and METABO finished
product was tested by an independent third party for
label claim and was shown to be within +/- 1% to 4.3%Figure 1 Supplement Facts panel for METABO.of the actual formulation for the main bioactive ingredi-
ents (Eurofins Scientific Inc., Petaluma, CA; Samples: #
740-2011-00007867 and #740-2011-00007868).
The study intervention included an 8-week diet and
exercise program consisting of recreationally active men
and women, randomly assigned to receive either a pla-
cebo or the manufacturer recommended dosage of their
respective supplement (two capsules with breakfast and
two capsules with lunch). Prior to starting the study, a
state-licensed, registered dietitian designed a target diet
to provide approximately 500 kilocalories per day less
than each subject’s estimated daily caloric requirement
as estimated by the Mifflin-St. Jeor equation [23] x an
activity factor of 1.2. In an effort to decrease variability,
the 500 kcal deficit was prescribed consistently to every
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the Mifflin-St. Jeor equation, as opposed to targeting the
500 kcal deficit to their baseline 3-day diet records. Each
subject was given seven days of menus based off their
daily allowance for calories. All menus consisted of three
meals and two snacks and targeted a 40% carbohydrate,
30% protein and 30% fat eating plan. Each study partici-
pant was contacted on a weekly basis to assess compliance
to diet and supplement protocol. Subjects performed
three, 60-minute exercise sessions per week using a ‘boot
camp’ type of training. A typical class consisted of the
following format: 10 minute warm-up (i.e. walking, light
jogging, or biking); 30 minutes of circuit training (upper
and lower body each session) composed of the following
exercises: mountain climbers, squat thrusts, jumping
jacks, squat kickouts, walking lunges, push-ups, dips, re-
sistance band elbow flexion, extension and shoulder
presses; 10 minutes abdominals/core, and 10 minutes cool
down/stretching. Based on pilot data monitoring heart
rate, this type of training expends approximately 300-
400 kcal/session. Every training session was supervised by
a certified fitness professional and conducted at a single
local facility to verify participation, and all subjects trained
as one group. The fitness professional used a participant
attendance log to monitor training compliance. All sub-
jects had measurements of their weight, BMI, waist and
hip girths, body fat and lean mass taken at week 0 (base-
line), week 4 (midpoint of the study) and week 8 (end of
the study). A member of the research staff contacted all
subjects on a weekly basis to ensure compliance to the
supplementation protocol, and pill counts were performed
during mid and post testing.
Blood samples were drawn at week 0 and week 8 for
standard assessment of clinical laboratory parameters (i.e.
comprehensive metabolic panel, lipid panel) and at weeks
0, 4 and 8 for serum concentrations of adipocytokines
(adiponectin, resistin, leptin, tumor necrosis factor-α
(TNF-α) and interleukin-6 (IL-6)). Vital signs, including
blood pressure and heart rate, were also recorded at weeks
0, 4 and 8. For each laboratory session, subjects reported
to the laboratory normally hydrated (ad libitum water
intake recorded prior to baseline testing and repeated
prior to week 4 and week 8 testing), 12 hours postprandial
and at least 48-hours following their last exercise session.
All measurements were completed by the same researcher
to minimize between-trial variation.
Energy levels and food craving data were analyzed
using a whole unit Likert-type scale [24]. Food craving
was defined as “an intense desire for a specific food that is
difficult to resist.” Subjects rated the frequency of cravings
ranging from 1 (“not at all”) to 5 (“nearly every day”). The
Food Craving Inventory consists of five factors or scales
measuring cravings for Sweets, Fast Food Fats, Fats (High
Fats), Carbs (carbohydrates/starches) and Healthy foods[24]. All energy levels and food craving data were collected
at weeks 0, 4 and 8.
Dependent variables
Sera and plasma variables were measured from 20 mL
(10 mL for sera and 10 mL for plasma) of blood drawn
with stasis via venipuncture of an antecubital vein. All
blood samples were taken in the morning at approxi-
mately the same time of day (i.e., between 0600 and
1000 h for all subjects, ± 60 min window of their initial
visit) to minimize diurnal variation, and subjects used
their target dietary recommendations (pre-intervention)
to standardize their evening meal, including fluid intake,
before mid (week 4) and post (week 8) testing. Blood
samples were harvested into 10 mL into BD Vacutainer W
tubes with and without EDTA, chilled on ice for 15
minutes, and then centrifuged (Drucker Model 614,
Philipsburg, PA) at room temperature for 15 minutes at
1200 × g to obtain plasma and serum, and immediately
placed into two aliquots. One aliquot was immediately
analyzed for a 21-item clinical chemistry profile
(Hitachi D2400, Roche Diagnostics, Germany) by a cer-
tified clinical laboratory. This profile consisted of a
comprehensive metabolic panel (glucose, BUN, creatin-
ine, sodium, potassium, chloride, carbon dioxide, cal-
cium, total protein, albumin, globulin, total bilirubin,
alkaline phosphatase, AST [SGOT], and ALT [SGPT])
as well as a lipid profile (total cholesterol, HDL-C, LDL-C,
VLDL-C, triacylglycerols [TAG]). The second aliquot
was stored at -80°C until later batch analysis for serum
adipokines (adiponectin, resistin, leptin, TNF-α, IL-6)
via enzyme-linked immunosorbent assay. Adipokines
were analyzed using a MAGPIXW (Luminex Corporation,
Austin, TX) and customized commercially available
magnetic bead panels (Millipore Corporation, Billerica,
MA). Adiponectin and resistin were analyzed with a
Human Adipokine Magnetic Bead Panel 1 (Millipore
catalog # HADK1MAG-61 K), while IL-6, TNF-alpha, and
leptin were analyzed with a Human Adipokine Magnetic
Bead Panel 2 (Millipore catalog # HADK2MAG-61 K).
Prior to each assay, the MAGPIX was calibrated using the
MAGPIX Calibration Kit (Millipore catalog # 40-049) and
performance verified using the MAGPIX Performance
Verification Kit (Millipore catalog # 40-050). Each assay
was run in one batch, therefore no inter-assay CV was
determined. Intra-assay CV was 4% for adiponectin and
3% for resistin, while CVs for IL-6, TNF-alpha, and
leptin were 2%, 3%, and 5%, respectively.
Body weight and height were determined on a calibrated
Seca 767™ Medical Scale and a wall-mounted stadiometer,
respectively. Body mass index was calculated as: BMI =
(weight in kg)/(height in m2). Lean mass, percent body fat
and trunk limb fat ratios were assessed using dual energy
x-ray absorptiometry (DEXA, GE Lunar, DPX Pro). All
Table 1 Baseline characteristics of subjects
Variable Placebo (n = 18) METABO (n = 27)
Age (y) 34.9 ± 5.7 35.9 ± 5.9
Height (m) 1.72 ± 0.1 1.73 ± 0.1
Body mass (kg) 91.0 ± 25.1 94.3 ± 23.3
BMI (kg/m2) 30.8 ± 2.5 31.5 ± 2.3
Fat mass (kg) 32.56 ± 13.5 37.18 ± 14.9
Lean mass (kg) 50.47 ± 13.6 52.81 ± 13.5
Lean:fat ratio 1.78 ± 0.77 1.61 ± 0.65
Waist (cm) 104.6 ± 18.3 104.1 ± 15.3
Hip (cm) 113.6 ± 15.1 114.3 ± 13.4
Waist:hip ratio 0.92 ± 0.16 0.91 ± 0.13
Systolic BP (mm Hg) 119 ± 11 120 ± 10
Diastolic BP (mm Hg) 80 ± 5 78 ± 9
Resting HR (beats/min) 69 ± 8 70 ± 8
Fasting glucose (mg/dL) 91 ± 8 90 ± 8
Values are mean ± SD.
Key: BMI, body mass index (body mass in kg/height in m2), BP, blood pressure,
HR, heart rate.
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analyzed via current manufacturer software (enCORE
version 13.31). Female subjects were measured during the
early follicular phase of their menstrual cycle, based on
reported last menstrual period, to minimize effects of
menstrual hormonal changes on dependent variables.
Briefly, subjects were positioned in the scanner according
to standard procedures and remained motionless for ap-
proximately 15 minutes during scanning. DEXA segments
for the arms, legs, and trunk were subsequently obtained
using standard anatomical landmarks. Percent fat was
calculated by dividing fat mass by the total scanned
mass. Quality control calibration procedures were
performed prior to all scans using a calibration block
provided by the manufacturer. Prior to this study, we
determined test-retest reliability for repeated measure-
ments of lean mass, bone mineral content, and fat mass
with this DEXA via intra-class correlation coefficients
[25]. All values were > 0.98.
Waist girth (defined as the narrowest part of the trunk
between the bottom of the rib cage and the top of the pel-
vis) and hip girth (defined as the largest laterally projecting
prominence of the pelvis or pelvic region from the waist
to the thigh) were measured in duplicate using standard-
ized anthropometric procedures [26]. Seated, resting heart
rate and blood pressure were measured in duplicate using
an automated sphygmomanometer (Omron HEM-711).
A baseline 3-d food record was completed for each sub-
ject after screening and enrollment, prior to randomization
and intervention. To verify dietary compliance, subjects
completed 3-d food records (which included two weekdays
and one weekend day) during baseline testing, week 4, and
week 8. All food records were analyzed by a state-licensed,
registered dietitian using commercially available software
(NutriBase IV Clinical Edition, AZ). To enhance accuracy
of the food records, all subjects received instruction during
baseline testing on how to accurately estimate portion
sizes. This counseling was reinforced during each visit to
the laboratory. No other dietary supplements were allowed
with the exception of standard strength multivitamins.
Safety analysis
Safety and tolerability of the supplements were assessed
through adverse event reports that were coded using the
Medical Dictionary for Regulatory Activities (MedDRA).
The intensity of an adverse event was graded according
to the protocol-defined toxicity criteria based on the
2009 DAIDS Therapeutic Research Program’s “Table for
Grading Severity of Adult Adverse Experiences [27].”
Statistical analyses
Descriptive data are summarized using mean ± standard
deviation (SD). Differences between groups from baseline
to week 4 and baseline to week 8 were analyzed usinganalysis of covariance (ANCOVA) with the baseline scores
employed as the covariate. All analyses were verified to
meet the homogeneity of regression assumption (parallel-
ism) of ANCOVA. Non-normally distributed variables
were log-transformed before analysis. For descriptive
purposes, raw values as well as the change scores (week 4
minus baseline, week 8 minus baseline) of all dependent
variables are displayed. Statistical significance was
accepted when the probability of a type 1 error was less
than or equal to 0.05 (p ≤ 0.05). Data were analyzed
using statistical software written using LabVIEW (Na-
tional Instruments, Austin TX) programming software.
Our a priori power analysis indicated that approximately
42 total subjects were required to have an 80% chance of
detecting, at the 5% level of significance, a difference be-
tween the two groups in body fat mass of 3 kg. However, a
goal of 70 total subjects were be enrolled due to higher
expected attrition from a study involving multiple inde-
pendent variables including a prescribed diet, regular exer-
cise, and supplement intervention.
Results
Subjects
Of the 70 subjects initially recruited, 25 were lost due to
attrition (i.e., poor compliance to the diet [n = 11], supple-
ment regimen [n = 12], exercise program [n = 7], request
to withdraw [4], and pregnancy [n = 1]). Of the 45 subjects
who completed the study, the group who received placebo
consisted of n = 18, seven male and 11 female subjects.
The group who received METABO consisted of n = 27,
12 male and 15 female subjects. Subject demographics
were similar between the two groups (Table 1).
Table 2 Anthropometric variables of METABO and placebo groups from week 0 through week 8
Variable METABO Placebo P
n = 27 n = 18 Value1
Baseline Mid point End of study Baseline Mid point End of study
(Week 0) (Week 4) (Week 8) (Week 0) (Week 4) (Week 8)
Body weight (kg) 94.1 ± 23.3 92.5 ± 23.1 92.2 ± 23.3 90.7 ± 25.1 90.1 ± 24.7 90.3 ± 24.8 0.10, 0.01*
Fat mass (kg) 37.2 ± 14.9 35.5 ± 14.7 34.3 ± 14.8 32.6 ± 13.5 31.4 ± 12.7 31.7 ± 12.7 0.16, 0.001*
Lean mass (kg) 52.8 ± 13.5 53.3 ± 14.1 54.6 ± 13.8 50.5 ± 13.6 50.7 ± 13.8 50.9 ± 13.6 0.72, 0.03*
Waist (cm) 104.1 ± 15.3 102.7 ± 15.1 102.0 ± 14.7 104.6 ± 18.3 104.2 ± 15.1 104.3 ± 18.1 0.004*, 0.0007*
Hip (cm) 114.3 ± 13.4 113.4 ± 13.2 112.4 ± 13.5 113.6 ± 15.1 113.2 ± 14.9 113.2 ± 14.9 0.04*, 0.0003*
Values are mean ± SD.
1P values are for the differences between the two groups, METABO versus placebo.
*Significant result P < 0.05 via ANCOVA (i.e., week 4 and week 8 time points are significantly different from each other after using the week 0 time point as
the covariate).
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Anthropometric variables are presented in Table 2. Sta-
tistically significant decreases were observed from week
0 to week 8 for subjects who received METABO versus
those who received placebo in body weight (-2.0% ver-
sus - 0.5%; p < 0.01, Figure 2); fat mass (-7.8% versus
-2.8%; p < 0.001, Figure 3); waist girth (-2.0% versus -0
.2%; p < 0.0007, Figure 4) and hip girth (-1.7% versus -0
.4%; p < 0.0003, Figure 5). Subjects who received
METABO exhibited statistically significant increases in
lean mass compared to those who received placebo
(+3.4% versus +0.8%; p < 0.03, Figure 6). The lean/fat ra-
tio of subjects who received METABO also increased
significantly more (+14.3%) compared to subjects who
received placebo (+3.4%, p < 0.001, Figure 7).
From week 0 to week 4 the mean differences in decreased
waist girths for the subjects who received METABO
versus those who received placebo were -1.36% and -0.4%,
respectively, and the differences between groups were
statistically significant (p < 0.004). Similarly, the mean
differences in decreased hip girths for the subjects who




























Figure 2 Mean ± SD changes in body weight, relative-to-baseline, in s
significant difference (P < 0.05) between groups during the post time pointwere -0.8% and -0.4%, respectively, and were statistically
significant (p < 0.045). However, from week 0 to week
4 there were no statistically significant differences in
body weight (p < 0.11), fat mass (p < 0.18), or lean
mass (p < 0.72) between groups.
Dietary variables
The macronutrient intake for METABO and placebo
groups, at baseline (pre-intervention) and at the end of
study based on 3-day food records is summarized in Table 3.
The mean target daily dietary intake (calculated using the
Mifflin-St. Jeor equation x 1.2 activity factor – 500 kcals)
for METABO was 1955 kcal, 195 g carbohydrates, 147 g
protein, and 87 g of fat. The target intake for placebo was
1907 kcal, 191 g carbohydrates, 143 g of protein, and 85 g
of fat. No differences were observed in energy consump-
tion, or in absolute or relative amounts of dietary carbohy-
drate, protein or fat between METABO and placebo.
Metabolic variables
The effects of the diet + exercise + supplement regimen

































Figure 3 Mean ± SD changes in body fat mass, relative-to-baseline, in subjects who received METABO and placebo. * indicates
statistically significant difference (P < 0.05) between groups at the post time point via ANCOVA.
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terol/HDL ratio and TAG, baseline levels in both groups
were within normal ranges and did not significantly differ
between them. Blood glucose increased slightly in both
groups from week 0 to week 8 but these differences were
not statistically significant (p < 0.60).
Concentrations of adipokine levels from week 0 to week
8 are also presented in Table 4. Serum leptin concentra-
tions were not significantly different between the two
groups from week 0 to week 8 but elevated serum concen-
trations of leptin were observed from week 0 to week 4 in
METABO (p < 0.03) versus the placebo group. Resistin
concentrations were normal in both groups and no signifi-
cant treatment effects were observed, however decreased
serum resistin concentrations from week 0 to week 4
























Figure 4 Mean ± SD changes in waist girth, relative-to-baseline, in sub
significant difference (P < 0.05) between groups at the post time point viaweek 0 to week 8 there were no differences in serum
concentrations of adiponectin (p < 0.15), IL-6 (p < 0.89),
or TNF-α (p < 0.49) noted between groups.
Energy levels and food cravings
Energy and food craving analyses from week 0 to week 8
are summarized in Table 5. Subjects who received
METABO exhibited a statistically significant increase in
relative energy levels (+ 29.3% versus +5.1%, respectively;
p < 0.02, Figure 8). Subjects who received METABO also
exhibited a statistically significant decrease in relative
fats cravings compared to the placebo group (-13.9%
versus -0.9%, respectively; p < 0.03, Figure 9). No statisti-
cally significant differences between the two groups were





































Figure 5 Mean ± SD changes in hip girth, relative-to-baseline, in subjects who received METABO and placebo. * indicates statistically
significant difference (P < 0.05) between groups at the mid and post time points via ANCOVA.
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No serious adverse events occurred during this study
and analyses of standard clinical chemistry panels of
serum and plasma revealed no statistically significant
abnormalities of clinical importance. There were no sig-
nificant between group effects for any cardiovascular
variable during the 8-week trial, and the changes within
groups were modest and non-significant. For resting
systolic blood pressure, the placebo group went from
119.3 + 11.5 mmHg to 121.2 + 10.6 mmHg while the
METABO™ group changed from 119.8 + 10.0 to 118.1 +
10.3 mmHg. Similarly, for resting diastolic blood pres-
sure the placebo group dropped from 80.3 + 5.2 to 76.1 +
6.3 mmHg while the METABO™ group fell from 77.8 +
8.7 to 76.9 + 9.1 mmHg. For resting heart rate, the placebo
group went from 69.4 + 8.4 to 69.9 + 7.9 beats/min while
the METABO™ group did not experience a mean





















Figure 6 Mean ± SD changes in lean body mass, relative-to-baseline,
statistically significant difference (P < 0.05) between groups at the post timincidence of non-serious adverse events (e.g., stomach
upset, etc.) were transient and similar, with no signifi-
cant differences between placebo and METABO.
Discussion
The results from this study demonstrate that as an adjunct
to an 8-week diet and weight loss program, administration
of METABO significantly decreases body weight, body fat
mass, waist and hip girth, while increasing lean mass com-
pared to the placebo. Although a restricted diet can
lead to weight loss, it is often accompanied by a loss of
lean tissue [28-30], which can have deleterious meta-
bolic consequences. Because of this, it is important to
achieve weight loss with a high ratio of fat to lean mass
loss that is essential for both short-term efficacy and
long-term metabolic health and body weight mainten-
ance [31,32]. In this study, overweight subjects who re-
ceived METABO achieved significantly greaterPost
Placebo
METABO*
in subjects who received METABO and placebo. * indicates






















Figure 7 Mean ± SD changes in lean mass-to-fat mass ratio, relative-to-baseline, in subjects who received METABO and placebo. *
indicates statistically significant difference (P < 0.05) between groups at the post time point via ANCOVA.
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Future studies should follow subjects during a washout
period to determine if this effect helps maintain long-
term weight control (i.e. minimize weight re-gain).
Additionally, a future investigation should include a
METABO only group with dietary control and no
structured exercise program to explore the role of diet
with METABO alone on body composition and meta-
bolic outcomes.
Neither placebo nor METABO administration affected
concentrations of blood lipids, including cholesterol,
HDL, LDL, cholesterol/HDL ratio and TAG, although
there was a strong trend (p < 0.07) for TAG concentra-
tions to decrease more in the METABO group (-15.9%)
compared to the placebo group (-2.6%). Future studies
may attempt to explore this observation further withTable 3 Dietary intake of METABO and placebo groups from
Variable METABO
n = 27
(Baseline) Pre-intervention Mid point End of stud
(Week 0) (Week 4) (Week 8)
Energy (kcal/d) 1831 ± 491 1889 ± 428 1912 ± 423
Carbohydrate (g/d) 206 ± 78 188 ± 58 188 ± 57
Carbohydrate (%) 46 ± 14 39 ± 6 39 ± 5
Fat (g/d) 54 ± 20 56 ± 17 57 ± 15
Fat (%) 26 ± 7 27 ± 4 27 ± 4
Protein (g/d) 130 ± 66 158 ± 43 162 ± 47
Protein (%) 28 ± 12 34 ± 8 34 ± 7
Values are mean ± SD.
1P values are for the differences between the two groups, METABO versus placebo
at week 4 or week 8 time points were noted using ANCOVA (where the week 0 tim
each subject after baseline 3-day food records (pre-intervention) using the Mifflin-S
macronutrient ratio of 40% carbohydrate, 30% fat and 30% protein.studies designed to look for differences in these import-
ant metabolic and biochemical markers as primary out-
come measures.
Another important finding in our study relates to the
observed differences in adipokine concentrations in the
METABO group, although most of these did not achieve
statistical significance. For example, we observed a trend
for decreased serum resistin concentrations in subjects
who received METABO compared to placebo at week 4,
but not week 8. High serum resistin concentrations have
been found in obese individuals and have been linked to
insulin resistance, hence the trend for decreased resistin
levels in METABO is an intriguing finding that requires
further investigation in a future study [33]. The current
study may have been underpowered to detect significant
differences in serum adiponectin, given that fat lossweek 0 through week 8 using 3-day food records
Placebo P
n = 18 Value1
y (Baseline) Pre-intervention Mid point End of study
(Week 0) (Week 4) (Week 8)
1764 ± 482 1913 ± 432 1917 ± 479 0.48, 0.41
215 ± 94 191 ± 58 202 ± 61 0.94, 0.80
48 ± 15 40 ± 6 42 ± 5 0.70, 0.90
52 ± 23 57 ± 13 56 ± 13 0.87, 0.85
27 ± 10 27 ± 4 27 ± 4 0.98, 0.79
110 ± 50 161 ± 47 150 ± 50 0.77, 0.66
26 ± 13 34 ± 7 31 ± 6 0.52, 0.99
at week 4 and week 8, respectively. No significant between group differences
e points were used as the covariate). Target dietary intake was provided to
t. Jeor equation plus an activity factor of 1.2 minus 500 kcal/day, with a
Table 4 Metabolic variables of METABO and placebo groups from week 0 through week 8
Blood lipid METABO Placebo P
n = 27 n = 18 Value1
Baseline Mid point End of study % Baseline Mid point End of study %
(Week 0) (Week 4) (Week 8) Change (Week 0) (Week 4) (Week 8) Change
Cholesterol, (mg/dL) 178.33 ± 26.49 NP 173.30 ± 30.25 -2.8 175.78 ± 31.45 NP 176.50 ± 31.14 0.4 0.3
HDL (mg/dL) 48.44 ± 12.47 NP 48.56 ± 15.26 0.2 50.28 ± 10.86 NP 48.94 ± 12.06 -2.7 0.49
LDL (mg/dL) 103.96 ± 26.04 NP 103.00 ± 30.92 -0.9 100.94 ± 28.53 NP 100.78 ± 30.17 -0.1 0.88
Cholesterol: HDL Ratio 3.91 ± 1.15 NP 3.85 ± 1.24 -1.5 3.67 ± 1.16 NP 3.87 ± 1.44 1.2 0.15
TAG (mg/dL) 118.44 ± 40.42 NP 99.59 ± 44.77 -15.9 120.22 ± 67.45 NP 117.06 ± 63.39 -2.6 0.07
Glucose (mg/dL) 89.81 ± 8.04 NP 92.67 ± 7.74 3.2 90.56 ± 8.3 NP 94.56 ± 13.82 4.4 0.60
Adiponectin (pg/mL) 10.20 ± 0.81 10.16 ± 0.74 9.93 ± 0.76 -0.2 10.17 ± 8.80 10.05 ± 0.80 10.04 ± 0.83 -0.3 0.47, 0.15
Resistin (pg/mL) 82.74 ± 38.47 81.65 ± 36.72 69.63 ± 26.04 -15.8 86.77 ± 50.18 68.38 ± 32.11 81.57 ± 46.75 -5.9 0.08, 0.26
Leptin (pg/mL) 8.99 ± 0.88 8.93 ± 0.94 8.729 ± 1.25 -3.0 8.85 ± 1.09 8.36 ± 1.07 8.76 ± 1.25 -3.0 0.03*, 0.5
lL-6 (pg/mL) 0.45 ±0.83 0.37 ± 0.56 0.34 ± 0.94 -24.5 0.45 ± 1.22 0.38 ± 0.82 0.38 ± 1.44 -14.8 0.97, 0.89
TNF-α (pg/mL) 1.71 ± 1.16 1.45 ± 1.04 1.58 ± 1.08 -7.6 1.35 ± 1.82 1.53 ± 1.67 1.19 ± 1.25 -11.7 0.41, 0.49
Values are mean ± SD.
1P values are for the differences between the two groups, METABO versus placebo at week 4 and week 8, respectively. No significant differences between the
week 8 time points were noted using ANCOVA (where the week 0 time points were used as the covariate). *Significant difference at the week 4 mid time point
for Leptin using ANCOVA. NP: not performed; HDL: high density lipoprotein; LDL: low density lipoprotein; TAG: triacylglycerols; IL-6: interleukin-6; TNF-α: tumor
necrosis factor-α.
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and a consistent exercise program. In addition, trends
for maintaining elevated serum leptin (from week 0
to week 4) were observed in subjects who received
METABO compared to placebo. Leptin acts on receptors
in the hypothalamus to regulate appetite, energy expend-
iture, sympathetic tone and neuroendocrine function,
and circulating levels have been shown to decline in re-
sponse to caloric restriction or negative energy balance
[34]. Leptin deficiency has been shown to promote hunger
and food seeking behaviour, in addition to reduced
metabolic rate in humans [35]. Collectively, the trend for
resistin and significant change in leptin may help to partly
explain the effects of METABO on body composition.Table 5 Relative energy and food craving analyses of METAB
METABO
n = 27
Baseline Mid point End of study
(Week 0) (Week 4) (Week 8)
Energy 3.04 ± 0.9 3.7 ± 0.67 3.93 ± 0.62
Sweet 2.36 ± 0.8 2.05 ± 0.84 1.92 ± 0.91
FFF 2.85 ± 0.87 2.56 ± 0.94 2.35 ± 0.92
Fats 2.16 ± 0.85 1.92 ± 0.77 1.86 ± 0.8
Carbs 2.26 ± 0.81 2.07 ± 0.74 2.01 ± 0.8
Healthy 2.44 ± 0.77 2.41 ± 0.72 2.38 ± 0.73
Values are mean ± SD.
1P values are for the differences between the two groups, METABO versus placebo
*Significant result via ANCOVA (i.e. week 8 time points are significantly different fro
FFF, fast food fats; Fats: total fats; Carbs: carbohydrates.The combination of ingredients with potentially comple-
mentary and interactive mechanisms of action may ac-
count for the favorable changes observed in many of the
clinical endpoints in the METABO group. Razberi-KW
contains Raspberry ketone (4-(4-hydroxyphenyl) butan-
2-one), which is a naturally occurring phenolic compound
in red raspberry (Rubus ideas) that has been shown to
enhance norepinephrine-induced lipolysis in adipocytes,
prevent high-fat diet-induced body weight gain in mice,
and increase adiponectin gene expression and secretion in
adipocytes in culture [12,13]. Moreover, Wang et al. dem-
onstrated anti-inflammatory benefits, improved antioxi-
dant capacity, and enhanced leptin and insulin sensitivity
in Sprague-Dawly rats using a high-fat diet inducedO and placebo groups from week 0 through week 8
Placebo P
n = 18 Value1
Baseline Mid point End of study
(Week 0) (Week 4) (Week 8)
3.33 ± 0.69 3.67 ± 0.84 3.5 ± 0.92 0.22, 0.02*
2.48 ± 0.81 2.02 ± 0.84 2.12 ± 0.71 0.58, 0.30
2.9 ± 0.54 2.28 ± 0.83 2.53 ± 0.68 0.48, 0.48
2.04 ± 0.49 1.97 ± 0.46 2.02 ± 0.56 0.12, 0.03*
2.52 ± 0.64 2.1 ± 0.7 2.21 ± 0.61 0.86, 0.92
2.56 ± 0.49 2.21 ± 0.78 2.43 ± 0.51 0.42, 0.92
at week 4 and week 8, respectively.
























Figure 8 Mean ± SD changes in energy levels, relative-to-baseline, in subjects who received METABO and placebo. * indicates statistically
significant difference (P < 0.05) between groups at the post time point via ANCOVA.
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http://www.jissn.com/content/10/1/22nonalcoholic steatohepatitis (NASH) model [36]. From
the limited preclinical literature, it appears that raspberry
ketones require norepinephrine for maximizing their
hormone-sensitive lipolytic action. CapsimaxW is a con-
centrated capsicum extract found in an encapsulated
beadlet form to decrease gastric irritation. Capsaicinoids
have been shown in animal studies to activate TRPV1 re-
ceptors in vagal afferents of the gut, leading to sympatho-
mimetic action with reductions in abdominal/visceral fat
[37]. There have been a number of short-term human
clinical studies utilizing between 2 mg/day and 10 mg/day
of active capsaicinoids that have reproduced some of these
preclinical animal efficacy and human clinical studies
[37-39] including increases in norepinephrine secretion
[15,17]. Further, a systematic review of 90 clinical trials,
20 of which were selected for inclusion demonstrated
that capsaicinoid consumption of greater than 2 mg/day



















Figure 9 Mean ± SD changes in fat cravings, relative-to-baseline, in su
significant difference (P < 0.05) between groups at the post time point viaimately 50 kcal/day and concentrations of anorexigenic
hormone glucagon-like peptide-1 [37,39]. Moreover, sig-
nificant decreases in energy intake of up to 8%, reductions
in preoccupation with food and desire for fatty foods have
been reported [39] that appears consistent with our food
craving analyses in the METABO group (Table 5).
Advantra ZW is an ingredient extracted from the Citrus
aurantium (traditional Chinese herb known as zhi-shi)
and standardized for the bioactive alkaloid p-synephrine.
Other alkaloids are present in the extract including:
octopamine, hordenine, and n-methyltyramine. Taken
together, the bioactive amines found in Advantra ZW
have been shown to increase thermogenesis, and there is
cell and tissue culture evidence to suggest lipolysis is ac-
celerated via a β3 adrenergic receptor pathway [40]. A re-
cent systematic review of human clinical studies involving
Citrus aurantium with its primary p-synephrine alkaloid




bjects who received METABO and placebo. * indicates statistically
ANCOVA.
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http://www.jissn.com/content/10/1/22reliable increases in resting metabolic rate of between
2.41% and greater than 7.2%, energy expenditure of up to
13.4%, and weight loss of over 2.9 kg, with no serious ad-
verse events affecting hemodynamic, electrocardiographic,
hematologic or clinical chemistry biomarkers when ad-
ministered over the course of 6-12 weeks [22].
Caffeine is regarded as one of the most commonly
consumed methylxanthine alkaloids known to act as an
adenosine receptor antagonist and phosphodiesterase
inhibitor. As such, the presence of caffeine may have
contributed to amplifying the beta-adrenergic and lipo-
lytic effects of the METABO formulation. Despite being
on a calorie-reduced diet, subjects in this study reported
feeling improved energy and decrease in cravings for
energy-dense, fatty foods. Previous studies have indi-
cated that food cravings are significantly related to food
intake with specific cravings correlating with types of
food consumed [24] and a high-fat diet is a strong risk
factor for the development of obesity and metabolic
syndrome, as a result of increased energy density and
overall caloric intake [41]. Caffeine, in isolation or in
combination with other bioactive nutritional com-
pounds, has also been shown in multiple human clinical
trials to increase the perception of energy, blunt appe-
tite, and improve measures of mood, alertness, atten-
tion, and concentration [14,42,43]. Caffeine may be a
thermogenic potentiator in METABO, as it has been
shown to increase energy expenditure by 4-5% and fat
oxidation by 10-16%, in addition to enhancing endur-
ance and high-intensity exercise performance [44,45].
Although subject demographics were similar between
groups, there was greater attrition of the placebo group
relative to METABO. Most of the attrition was the result
of poor compliance with the diet, supplement and/or ex-
ercise program. It has been reported that decreased
levels of mental and physical energy and increased crav-
ings for energy-dense foods can diminish dietary and ex-
ercise adherence during outpatient weight loss programs
[46,47]. A notable finding in this regard is that, com-
pared to the placebo group, the METABO group experi-
enced a significant increase in their energy levels and
decreased cravings for energy-dense foods. Future studies
may examine if METABO improves adherence to a com-
prehensive diet and exercise weight loss program. Gender
differences were not explored in our study, but future
investigations are currently underway in an attempt to
answer this question.
The authors would like to clarify why the data
presented in Table 3 does not appear to underfeed each
subject by 500 kcals/day. The mean target caloric intake
for the METABO group using the Mifflin-St. Jeor equation
multiplied by an activity factor of 1.2 –(minus) 500 kcal
equals 1955 kcal/day. The target intake for placebo using
same method was 1907 kcal/day. We realize these targetsare greater than the mean of each group’s reported base-
line caloric intake based on three-day food records. How-
ever, three-day food records are notorious for recall bias
and an underestimation of actual energy consumption
[48]. Thus, it is not surprising that both groups moved
closer to their “target” kcal/day intake over the course of
this 8 week study. The target caloric intakes being greater
than the reported intakes from baseline (pre-intervention)
three-day food records helps to explain why both groups
may have actually increased their reported intakes by 4%
and 9% for METABO and placebo, respectively. Therefore,
it is plausible that subjects in both groups may have expe-
rienced even more dramatic body composition and/or
metabolic benefits had the 500 kcal deficit been applied to
their baseline, reported intakes as opposed to their
estimated caloric requirements obtained via Mifflin-St.
Jeor equation.
The obese and overweight state is characterized by
chronic, low-grade systemic inflammation as a result of
the expanded white adipose tissue compartment, particu-
larly the visceral adipose depot. Adipose tissue from obese
individuals is known to be an important endocrine organ
capable of contributing to insulin resistance, persistent in-
flammation, and metabolic and vascular dysfunction via the
perturbed adipokine secretion profile [34]. The collective
action of garlic extract standardized for organosulfur com-
pounds, ginger extract standardized for gingerols and
shogaols, biotin and chromium in METABO may contrib-
ute to antiadipogenic, anti-inflammatory actions in con-
junction with metabolic health benefits [20,21,36,37,49-51].
The bioactive compounds in garlic, ginger, and rasp-
berry in addition to biotin and chromium have been
suggested to modulate high-leverage metabolic path-
ways with nutrigenomic signaling, including: NF-kB,
PPAR-γ, PPAR-α, orexigens, and aforementioned adipo-
cytokines. It is conceivable that although increased
sympathomimetic drive, lipolysis and thermogenesis
contributed to the positive outcomes in body composition,
the interaction of reduced dietary energy intake with exer-
cise and METABO lead to further improvements in the
adipokine profile that facilitated improvements in serum
triacylglycerol, selective fat loss, skeletal muscle retention
and abdominal girth reduction. It would be helpful for fu-
ture studies to explore the influence of METABO on the
systemic adipokine profile to clarify if this is one potential
mechanism.
Conclusion
In recent years, there have been numerous natural prod-
ucts being marketed and sold that claim to contain the
right combination of vitamins, herbs and foods that can
help with weight loss. However, very few of these prod-
ucts undergo finished product-specific research demon-
strating their efficacy and safety. In the current study, as
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METABO administration augmented beneficial changes
in body composition and anthropometric variables (hip
and waist girth) in overweight men and women, and led
to additional benefits on energy levels and food cravings.
The placebo group had noticeable beneficial changes in
body fat and non-significant improvements in certain
metabolic variables as a result of diet and exercise alone,
albeit these changes were less robust than in METABO
group. METABO was safe and well-tolerated in all sub-
jects, no serious adverse events were recorded, nor were
differences in systemic hemodynamics or clinical blood
chemistries observed between the two groups. Further
studies are required to clarify the mechanisms by which
METABO exerts its weight loss effects and its possible
role in regulating adipokine concentrations.
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